Equities

Haemato AG

Haemato AG

Actions
  • Price (EUR)13.80
  • Today's Change-0.20 / -1.43%
  • Shares traded827.00
  • 1 Year change-32.35%
  • Beta1.5194
Data delayed at least 15 minutes, as of Nov 14 2024 10:58 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Haemato AG, previously Windsor AG, is a Germany-based pharmaceutical company. The Company trades and patent-free and patent-protected medicines and generic drugs with focus on oncology, human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS), neurology, rheumatology, urology, cardiovascular diseases and other chronic diseases. The Company's main markets are Europe, North America and Japan. It also imports medicines from within the European Economic Area in form of parallel imports and re-imports. The Company's subsidiaries are Haemato Pharm GmbH, Heamato Med GmbH, Castell Pharma BV, Sanate GmbH and Heamato Asia Co Ltd. Customers can order medicine through phone, fax and e-mail, among others.

  • Revenue in EUR (TTM)260.81m
  • Net income in EUR9.61m
  • Incorporated2003
  • Employees78.00
  • Location
    Haemato AGLilienthalstrasse 3aSCHOENEFELD 12529GermanyDEU
  • Phone+49 30 897308670
  • Fax+49 30 897308679
  • Websitehttps://haemato.ag/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
IND Swift Laboratories Ltd112.55m45.37m71.42m47.001.57--1.430.634668.5368.53170.41--------213,559,000.00--5.00--6.1347.5441.1240.368.52--4.68--0.006.1011.10784.4470.8223.60--
3D Medicines Inc63.96m-58.84m71.62m193.00--0.6456--1.12-2.06-2.062.203.530.37464.945.792,655,131.00-37.27---50.88--91.97---99.50--2.56--0.2517--11.91--48.78------
Journey Medical Corp73.53m797.99k72.17m58.0051.009.0718.590.9814-0.0131-0.01313.910.56421.152.365.711,339,328.001.25--5.17--66.79--1.09--1.082.000.6682--7.48--87.00------
Vita Life Sciences Limited48.45m5.78m72.25m124.0012.182.4211.901.490.17170.17171.440.8651.292.336.94--15.3715.2521.1821.9958.4860.9011.9011.712.18--0.008839.0510.8812.5028.1830.0712.1519.14
OptiNose Inc71.63m-29.49m72.39m132.00------1.01-0.2216-0.22160.5416-0.27250.65120.76592.96573,272.80-26.80-48.25---98.9590.2186.96-41.16-131.660.7198-1.611.48---6.9358.6452.58---27.96--
Haemato AG260.81m9.61m73.10m78.007.600.48836.790.28031.841.8450.1028.671.479.8012.483,343,690.005.412.016.452.707.568.423.681.211.66--0.0203157.20-12.95-3.0325.393.32-5.75-16.74
Bioceltix SA0.00-3.62m74.18m24.00--8.56-----3.78-3.780.009.120.00114.34--0.00-44.04---49.90----------3.27--0.0047-------53.42------
Data as of Nov 14 2024. Currency figures normalised to Haemato AG's reporting currency: Euro EUR

Institutional shareholders

0.00%Per cent of shares held by top holders
HolderShares% Held
Universal-Investment-Gesellschaft mbH (Invt Mgmt)as of 31 Mar 20240.000.00%
Do Investment AGas of 31 Dec 20230.000.00%
Data from 31 Dec 2023 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.